Sangamo Therapeutics (OTC: SGMOQ) posts $3.8M loss in early Chapter 11

Rhea-AI Filing Summary

Sangamo Therapeutics, Inc. reports initial Chapter 11 operating metrics for the period June 1–30, 2026, furnished via a monthly operating report. The company previously filed a voluntary Chapter 11 petition on June 23, 2026 in the District of Delaware.

During the month, Sangamo drew $10,500,000 under a senior secured superpriority debtor-in-possession term loan facility, driving total cash receipts to $10,503,072 against disbursements of $977,931. Cash increased from $4,857,102 to $14,382,243.

The report lists total assets of $153,087,245 and total liabilities of $89,151,054, including $10,987,803 of postpetition debt and $78,129,568 of prepetition unsecured debt. For the period, Sangamo recorded a net loss of $3,755,058, including $2,010,335 of reorganization items.

The company cautions that the MOR is unaudited, not prepared under U.S. GAAP, subject to change, and limited to bankruptcy reporting needs. It also warns that trading in its common stock, now quoted OTC under “SGMOQ” following Nasdaq suspension and delisting notice, is highly speculative and that trading prices may bear little or no relationship to any eventual recovery in the Chapter 11 case.

Positive

• None.

Negative

• Voluntary Chapter 11 filing and ongoing case — Sangamo is operating as a debtor-in-possession under Chapter 11 with a case pending in the District of Delaware, indicating significant financial distress and restructuring risk.
• Significant June 2026 net loss of $3,755,058 — For the June reporting period, the company generated minimal gross income of $108,953 and recorded a substantial loss driven by operating and reorganization expenses.
• High debt burden, largely unsecured prepetition — Total liabilities are $89,151,054, including $78,129,568 of prepetition unsecured debt and $10,987,803 of postpetition obligations, underscoring a heavy capital structure to be addressed in Chapter 11.
• Common stock delisted from Nasdaq and highly speculative — The company’s stock has been suspended and noticed for delisting from the Nasdaq Capital Market, now trades on the OTC Basic Market as “SGMOQ,” and management states that trading is highly speculative with prices potentially unrelated to ultimate recovery.
• Financial disclosures are limited and non-GAAP — Management emphasizes the MOR is unaudited, not prepared in accordance with U.S. GAAP, limited in scope, and subject to material adjustment, reducing visibility into the true economic position.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

DIP financing drawn: $10,500,000 Cash end of month: $14,382,243 Total assets: $153,087,245 +5 more

8 metrics

DIP financing drawn $10,500,000 Amount drawn under senior secured superpriority debtor-in-possession facility during June 23–30, 2026

Cash end of month $14,382,243 Cash balance at June 30, 2026 after Chapter 11 commencement

Total assets $153,087,245 Asset balance reported in Part 2 of the June 2026 monthly operating report

Total liabilities $89,151,054 Sum of postpetition and prepetition debt reported in Part 2 of the MOR

Prepetition unsecured debt $78,129,568 Prepetition unsecured obligations listed in Part 2 of the June 2026 MOR

Net loss for period $3,755,058 Profit (loss) figure for June 2026, including $2,010,335 of reorganization items

Reorganization items $2,010,335 Expenses specifically attributed to reorganization in the June 2026 income statement

Cash receipts $10,503,072 Total receipts during June 2026, net of transfers between accounts

Key Terms

debtor-in-possession term loan facility, superpriority administrative expense status, First Day Orders, Monthly Operating Report, +2 more

6 terms

debtor-in-possession term loan facility financial

"authorizing the Debtor to enter into a senior secured superpriority debtor-in-possession term loan facility"

superpriority administrative expense status regulatory

"Granting Liens and Providing Claims with Superpriority Administrative Expense Status"

First Day Orders regulatory

"Pursuant to certain orders of the Court in the Debtor’s chapter 11 case entered on or about June 24, 2026 (the “First Day Orders”)"

Monthly Operating Report financial

"the Company filed with the Bankruptcy Court its monthly operating report for the period"

reorganization items financial

"Reorganization items | | $ | 2,010,335"

Reorganization items are the one-time costs and adjustments a company records when it restructures its operations, such as employee severance, facility closures, asset write-downs, or contract termination fees. Investors care because these charges can make a period’s profit look worse even if they don’t reflect ongoing performance—think of them as the upfront bills for rearranging a business that may reduce future expenses or improve efficiency.

adequate assurance of payment regulatory

"interim order approving, among other things, the Debtor’s proposed form of adequate assurance of payment to utility companies"

FAQ

What did Sangamo Therapeutics (SGMOQ) disclose about its Chapter 11 status?

Sangamo Therapeutics disclosed it filed a voluntary Chapter 11 petition on June 23, 2026 in the District of Delaware and is operating as a debtor-in-possession. The August 6, 2026 monthly operating report provides initial postpetition cash, debt, and loss figures for June 2026.

How much cash did Sangamo Therapeutics (SGMOQ) have at June 30, 2026?

As of June 30, 2026, Sangamo reported a cash balance of $14,382,243, up from $4,857,102 at the beginning of June. The increase was primarily driven by a $10,500,000 draw under its debtor-in-possession financing facility.

What loss did Sangamo Therapeutics (SGMOQ) report for June 2026 in its MOR?

For the June 2026 reporting period, Sangamo reported a net loss of $3,755,058 on gross income of $108,953. Expenses included $1,096,018 of general and administrative costs and $2,010,335 of reorganization items tied to the Chapter 11 process.

What are Sangamo Therapeutics’ (SGMOQ) assets and liabilities in the Chapter 11 report?

Sangamo’s monthly report lists total assets of $153,087,245 and total liabilities of $89,151,054. Liabilities include $10,987,803 of postpetition debt and $78,129,568 of prepetition unsecured debt, reflecting a substantial obligation load.

How much debtor-in-possession (DIP) financing has Sangamo Therapeutics (SGMOQ) drawn?

Under a senior secured superpriority debtor-in-possession facility, Sangamo drew $10,500,000 during the June 23–30, 2026 period. The company states these funds are being used to support ongoing business operations and costs of the Chapter 11 case.

Where is Sangamo Therapeutics (SGMOQ) stock currently trading and what risks were noted?

Sangamo’s common stock has been suspended from the Nasdaq Capital Market and now trades on the OTC Basic Market as “SGMOQ”. The company warns that trading is highly speculative and prices may bear little or no relationship to any Chapter 11 recovery.

Is the Sangamo Therapeutics (SGMOQ) Monthly Operating Report prepared under U.S. GAAP?

No. Management notes the monthly operating report is unaudited, not prepared in accordance with U.S. GAAP, follows a bankruptcy-prescribed format, and is subject to future adjustment. It cautions that the report should not be relied upon for investment decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/12/2026 - 04:03 PM Accepted by SEC EDGAR 08/12/2026 - 04:02 PM Learn about SEC filing dates

SANGAMO THERAPEUTICS, INC NASDAQ false 0001001233 0001001233 2026-08-06 2026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2026

SANGAMO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		000-30171		68-0359556
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer ID Number)

501 Canal Blvd., Richmond, California 94804

(Address of principal executive offices) (Zip Code)

(510) 970-6000

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		SGMO		Nasdaq Capital Market *

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

* Following a determination by the Nasdaq Stock Market LLC (“Nasdaq”) to delist the common stock of Sangamo Therapeutics, Inc. (the “Company”), the Company’s common stock was suspended from trading on Nasdaq on May 5, 2026 and currently trades on the OTCID Basic Market under the symbol “SGMOQ”. On July 14, 2026, the Nasdaq Hearings Panel issued a written determination letter denying the Company’s request to continue its listing on Nasdaq.

Item 7.01 Regulation FD Disclosure.

As previously announced, on June 23, 2026, Sangamo Therapeutics, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the Company (the “Chapter 11 Case”). The case number is 26-10989 and the case is styled as In re Sangamo Therapeutics, Inc.

On August 6, 2026, the Company filed with the Bankruptcy Court its monthly operating report for the period beginning June 1, 2026 and ended June 30, 2026 (the “MOR”).

The information set forth in Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD. The MOR is attached hereto as Exhibit 99.1. The MOR and additional information regarding the Chapter 11 Case is available at https://www.veritaglobal.net/SangamoTherapeutics. The documents and other information on this website are not part of this Current Report on Form 8-K and shall not be incorporated by reference.

The information contained in this Item 7.01 and in Exhibit 99.1 is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Cautionary Statement Regarding the MOR

The Company cautions investors and potential investors not to place undue reliance upon the information contained in the MOR, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The MOR is limited in scope, covers a limited time period and has been prepared solely for the purpose of complying with the reporting requirements of the Bankruptcy Court. The MOR is not audited or reviewed by independent accountants, was not prepared in accordance with generally accepted accounting principles in the United States, is in a format prescribed by applicable bankruptcy laws or rules, and is subject to future adjustment and reconciliation. The MOR also contains information for periods shorter and otherwise different from those contained in the Company’s reports required to be filed pursuant to the Exchange Act. There can be no assurance that, from the perspective of an investor or potential investor in the Company’s securities, the MOR is complete. Results set forth in the MOR should not be viewed as indicative of future results.

Cautionary Language Regarding Trading in the Company’s Common Stock

The Company’s stockholders are cautioned that trading in the Company’s common stock during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. The Company’s common stock has been suspended from trading on, and the Company received a notice of delisting from, the Nasdaq Capital Market and is currently trading on the OTCID Basic Market under the symbol “SGMOQ,” and trading prices for the Company’s common stock may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company’s Chapter 11 Case. Accordingly, the Company urges extreme caution with respect to existing and future investments in its common stock.

Cautionary Language Regarding Forward-Looking Statements

This Current Report on Form 8-K contains certain forward-looking statements that reflect, when made, the Company’s current views with respect to current events and financial performance. These forward-looking statements are within the meaning of Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding process and potential outcomes of the Company’s Chapter 11 Case and/or statements preceded by, followed by or that include the words “intends,” “expects,” “estimates,” “plans,” or similar expressions. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, beliefs and expectations, there can be no assurance that its expectations will be achieved. Except as otherwise may be required by law, the Company undertakes no obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances, or changes in expectations after the date of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description of Document
99.1		Sangamo Therapeutics, Inc. Monthly Operating Report for the period ended June 30, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				SANGAMO THERAPEUTICS, INC.
Date: August 12, 2026				By:		/s/ SCOTT B. WILLOUGHBY
						Scott B. Willoughby
						Chief Legal Officer and Corporate Secretary

Exhibit 99.1

Case 26-10989-CTG Doc 268 Filed 08/06/26 Page 1 of 23

Docket #0238 Date Filed: 08/06/2026

UNITED STATES BANKRUPTCY COURT

      DISTRICT OF DELAWARE

In Re. SANGAMO THERAPEUTICS, INC.		§		Case No. 26-10989
		§
		§
Debtor(s)		§
				Jointly Administered

Monthly Operating Report						Chapter 11
Reporting Period Ended: 06/30/2026				Petition Date: 06/23/2026
Months Pending: 0				Industry Classification:
Reporting Method:		Accrual Basis		Cash Basis
Debtor’s Full-Time Employees (current):				73
Debtor’s Full-Time Employees (as of date of order for relief):				74

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

☒ Statement of cash receipts and disbursements

☒ Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit

☒ Statement of operations (profit or loss statement)

☐ Accounts receivable aging

☐ Postpetition liabilities aging

☐ Statement of capital assets

☐ Schedule of payments to professionals

☒ Schedule of payments to insiders

☒ All bank statements and bank reconciliations for the reporting period

☐ Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Nikunj Jain				Nikunj Jain
Signature of Responsible Party				Printed Name of Responsible Party
08/06/2026
Date
				501 Canal Blvd., Suite A100 Richmond, CA 94804
				Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. §1320.4(a)(2) applies.

UST Form 11-MOR (12/01/2021) 1

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 2 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

Part 1: Cash Receipts and Disbursements				Current Month				Cumulative
a.		Cash balance beginning of month		$	4,857,102
b.		Total receipts (net of transfers between accounts)		$	10,503,072			$	10,503,072
c.		Total disbursements (net of transfers between accounts)		$	977,931			$	977,931
d.		Cash balance end of month (a+b-c)		$	14,382,243
e.		Disbursements made by third party for the benefit of the estate		$	0			$	0
f.		Total disbursements for quarterly fee calculation (c+e)		$	977,931			$	977,931
Part 2: Asset and Liability Status (Not generally applicable to Individual Debtors. See Instructions.)				Current Month
a.		Accounts receivable (total net of allowance)		$	500,160
b.		Accounts receivable over 90 days outstanding (net of allowance)		$	90,355
c.		Inventory (Book Market Other (attach explanation))		$	0
d		Total current assets		$	18,185,639
e.		Total assets		$	153,087,245
f.		Postpetition payables (excluding taxes)		$	10,929,227
g.		Postpetition payables past due (excluding taxes)		$	0
h.		Postpetition taxes payable		$	58,576
i.		Postpetition taxes past due		$	0
j.		Total postpetition debt (f+h)		$	10,987,803
k.		Prepetition secured debt		$	0
l.		Prepetition priority debt		$	33,683
m.		Prepetition unsecured debt		$	78,129,568
n.		Total liabilities (debt) (j+k+l+m)		$	89,151,054
o.		Ending equity/net worth (e-n)		$	63,936,191
Part 3: Assets Sold or Transferred				Current Month				Cumulative
a.		Total cash sales price for assets sold/transferred outside the ordinary course of business		$	0			$	0
b.		Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business		$	0			$	0
c.		Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)		$	0			$	0
Part 4: Income Statement (Statement of Operations) (Not generally applicable to Individual Debtors. See Instructions.)				Current Month				Cumulative
a.		Gross income/sales (net of returns and allowances)		$	108,953
b.		Cost of goods sold (inclusive of depreciation, if applicable)		$	0
c.		Gross profit (a-b)		$	108,953
d.		Selling expenses		$	0
e.		General and administrative expenses		$	1,096,018
f.		Other expenses		$	918,433
g.		Depreciation and/or amortization (not included in 4b)		$	58,930
h.		Interest		$	0
i.		Taxes (local, state, and federal)		$	0
j.		Reorganization items		$	2,010,335
k.		Profit (loss)		$	-3,755,058			$	-3,755,058

UST Form 11-MOR (12/01/2021) 2

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 3 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

Part 5: Professional Fees and Expenses

Approved Current Month

Approved Cumulative

Paid Current Month

Paid Cumulative

a.

Debtor’s professional fees & expenses (bankruptcy) Aggregate Total

Itemized Breakdown by Firm

Firm Name

Role

i

ii

iii

iv

v

vi

vii

viii

ix

x

xi

xii

xiii

xiv

xv

xvi

xvii

xviii

xix

xx

xxi

xxii

xxiii

xxiv

xxv

xxvi

xxvii

xxviii

xxix

xxx

xxxi

xxxii

xxxiii

xxxiv

xxxv

xxxvi

UST Form 11-MOR (12/01/2021) 3

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 4 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

xxxvii

xxxvii

xxxix

xl

xli

xlii

xliii

xliv

xlv

xlvi

xlvii

xlviii

xlix

l

li

lii

liii

liv

lv

lvi

lvii

lviii

lix

lx

lxi

lxii

lxiii

lxiv

lxv

lxvi

lxvii

lxviii

lxix

lxx

lxxi

lxxii

lxxiii

lxxiv

lxxv

lxxvi

lxxvii

lxxviii

UST Form 11-MOR (12/01/2021) 4

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 5 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

lxxix

lxxx

lxxxi

lxxxii

lxxxiii

lxxxiv

lxxxv

lxxxvi

lxxxvi

lxxxvi

lxxxix

xc

xci

xcii

xciii

xciv

xcv

xcvi

xcvii

xcviii

xcix

c

ci

Approved Current Month

Approved Cumulative

Paid Current Month

Paid Cumulative

b.

Debtor’s professional fees & expenses (nonbankruptcy) Aggregate Total

Itemized Breakdown by Firm

Firm Name

Role

i

ii

iii

iv

v

vi

vii

viii

ix

x

xi

xii

xiii

xiv

UST Form 11-MOR (12/01/2021) 5

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 6 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

xv

xvi

xvii

xviii

xix

xx

xxi

xxii

xxiii

xxiv

xxv

xxvi

xxvii

xxviii

xxix

xxx

xxxi

xxxii

xxxiii

xxxiv

xxxv

xxxvi

xxxvii

xxxvii

xxxix

xl

xli

xlii

xliii

xliv

xlv

xlvi

xlvii

xlviii

xlix

l

li

lii

liii

liv

lv

lvi

UST Form 11-MOR (12/01/2021) 6

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 7 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

lvii

lviii

lix

lx

lxi

lxii

lxiii

lxiv

lxv

lxvi

lxvii

lxviii

lxix

lxx

lxxi

lxxii

lxxiii

lxxiv

lxxv

lxxvi

lxxvii

lxxviii

lxxix

lxxx

lxxxi

lxxxii

lxxxiii

lxxxiv

lxxxv

lxxxvi

lxxxvi

lxxxvi

lxxxix

xc

xci

xcii

xciii

xciv

xcv

xcvi

xcvii

xcviii

xcix

c

c.   All professional fees and expenses (debtor & committees)

$   0

$   0

$   0

$   0

UST Form 11-MOR (12/01/2021) 7

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 8 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

Part 6: Postpetition Taxes		Current Month				Cumulative
a.   Postpetition income taxes accrued (local, state, and federal)		$	0			$	0
b.  Postpetition income taxes paid (local, state, and federal)		$	0			$	0
c.   Postpetition employer payroll taxes accrued		$	55,439			$	55,439
d.  Postpetition employer payroll taxes paid		$	0			$	0
e.   Postpetition property taxes paid		$	0			$	0
f.   Postpetition other taxes accrued (local, state, and federal)		$	17,882			$	17,882
g.  Postpetition other taxes paid (local, state, and federal)		$	0			$	0

Part 7: Questionnaire - During this reporting period:
a.   Were any payments made on prepetition debt? (if yes, see Instructions)		Yes				No
b.  Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions)		Yes				No
c.   Were any payments made to or on behalf of insiders?		Yes				No
d.  Are you current on postpetition tax return filings?		Yes				No
e.   Are you current on postpetition estimated tax payments?		Yes				No
f.   Were all trust fund taxes remitted on a current basis?		Yes				No
g.  Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions)		Yes				No
h.  Were all payments made to or on behalf of professionals approved by the court?		Yes				No				N/A
i.   Do you have:     Worker’s compensation insurance?		Yes				No
If yes, are your premiums current?		Yes				No				N/A (if no, see Instructions)
Casualty/property insurance?		Yes				No
If yes, are your premiums current?		Yes				No				N/A (if no, see Instructions)
General liability insurance?		Yes				No
If yes, are your premiums current?		Yes				No				N/A (if no, see Instructions)
j.   Has a plan of reorganization been filed with the court?		Yes				No
k.  Has a disclosure statement been filed with the court?		Yes				No
l.   Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?		Yes				No

UST Form 11-MOR (12/01/2021) 8

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 9 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

Part 8: Individual Chapter 11 Debtors (Only)
a.   Gross income (receipts) from salary and wages								$   0
b.  Gross income (receipts) from self-employment								$   0
c.   Gross income from all other sources								$   0
d.  Total income in the reporting period (a+b+c)								$   0
e.   Payroll deductions								$   0
f.   Self-employment related expenses								$   0
g.  Living expenses								$   0
h.  All other expenses								$   0
i.   Total expenses in the reporting period (e+f+g+h)								$   0
j.   Difference between total income and total expenses (d-i)								$   0
k.  List the total amount of all postpetition debts that are past due								$   0
l.   Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)?		Yes		No
m.   If yes, have you made all Domestic Support Obligation payments?		Yes		No		N/A

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor’s progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee’s or examiner’s duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee’s systems of records notice, UST-001, “Bankruptcy Case Files and Associated Records.” See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/ eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

/s/ Nikunj Jain				Nikunj Jain
Signature of Responsible Party				Printed Name of Responsible Party
Interim Chief Financial Officer				08/06/2026
Title				Date

UST Form 11-MOR (12/01/2021) 9

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 10 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

UST Form 11-MOR (12/01/2021) 10

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 11 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

UST Form 11-MOR (12/01/2021) 11

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 12 of 23

Debtor’s Name SANGAMO THERAPEUTICS, INC. Case No. 26-10989

UST Form 11-MOR (12/01/2021) 12

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 13 of 23

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT DELAWARE

		)
In re:		)		Chapter 11
		)
SANGAMO THERAPEUTICS, INC.		)		Case No. 26-10989 (CTG)
		)
Debtor.1		)
		)

GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY, AND

DISCLAIMERS REGARDING THE DEBTOR’S MONTHLY OPERATING REPORT

On June 23, 2026 (the “Petition Date”), Sangamo Therapeutics, Inc. (the “Debtor”) commenced the above-captioned chapter 11 case by filing a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) with the United States Bankruptcy Court for the District of Delaware (the “Court”). The Debtor is authorized to operate its business as a debtor-in-possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

General Methodology

The Debtor is filing its monthly operating report (the “MOR”) for the period from the Petition Date through June 30, 2026 (the “Reporting Period”) for purposes of complying with the monthly reporting requirements applicable in the Debtor’s chapter 11 case. The MOR is unaudited and have not been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and do not include all of the information and footnotes required by U.S. GAAP. The MOR is not intended to reconcile to any financial statements otherwise prepared or distributed by the Debtor. The MOR should not be relied upon by any persons for information relating to current or future financial condition, events, or performance of any of the Debtor or its affiliates, as the results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the combined results of operations, financial position, and schedule of receipts and disbursements in the future.

Basis for Presentation

In preparing the MOR, the Debtor relied on financial information from its books and records at the time of such preparation. The financial information contained in the MOR is derived from the Debtor’s books and records without, among other things, all adjustments or reclassification that may be necessary or typical to accord with U.S. GAAP.

¹  The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The Debtor’s mailing address is 501 Canal Blvd., Ste A100, Richmond, CA 94804.

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 14 of 23

This information has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtor believes that the financial information presented in the MOR could be subject to change, including material change.

Although the Debtor made efforts to ensure the accuracy and completeness of the MOR, given the complexity of the Debtor’s business, inadvertent errors or omissions may occur. Accordingly, the Debtor hereby reserves all rights to dispute the nature, validity, status, enforceability, or executory nature of any claim amount, agreement, representation, or other statement set forth in the MOR. Further, the Debtor reserves the right to amend or supplement the MOR, if necessary, but shall be under no obligation to do so.

Moreover, given, among other things, the uncertainty surrounding the valuation and ownership of certain assets and the valuation and nature of certain liabilities, to the extent the Debtor shows more assets than liabilities, it is not an admission that the Debtor was solvent as of the Petition Date or at any time prior to the Petition Date. Likewise, to the extent the Debtor shows more liabilities than assets, it is not an admission that the Debtor was insolvent at the Petition Date or any time prior to the Petition Date.

For the reasons discussed above, there can be no assurance that the financial information presented in the MOR is complete, and readers are strongly cautioned not to place undue reliance on the MOR.

Each signatory to the MOR has necessarily relied upon the efforts, statements, advice, and representations of personnel of the Debtor and the Debtor’s advisors and professionals. Each signatory has not (and could not have) personally verified the accuracy of each such statement, representation, and answer contained in the MOR.

Reporting Period

Unless otherwise noted herein, the MOR generally reflects the Debtor’s books and records for the applicable Reporting Period. Unless otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

Accuracy

The financial information disclosed in the MOR was not prepared in accordance with federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling, or transferring the claims against or equity interests in the Debtor should evaluate the financial information in light of the purposes for which it was prepared. The Debtor and its advisors are not liable for and undertake no responsibility to indicate variations from securities laws in the MOR or for any evaluations of the Debtor, including of their financial condition, based on this financial information or any other information.

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 15 of 23

Debtor in Possession Financing

On June 25, 2026, the Court entered the Interim Order (A) Authorizing the Debtor to Obtain Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 63] (the “Initial Interim DIP Order”) authorizing the Debtor to enter into a senior secured superpriority debtor-in-possession term loan facility (the “Initial DIP Facility”).² During the reporting period, the Debtor drew $10,500,000 under the Initial DIP Facility. Please refer to the motion [Docket No. 10] seeking entry of the Initial Interim DIP Order for additional information regarding the Initial DIP Facility.

Payment of Prepetition Claims Pursuant to First Day Orders

Pursuant to certain orders of the Court in the Debtor’s chapter 11 case entered on or about June 24, 2026 (the “First Day Orders”), the Debtor is authorized (but not directed) to pay, among other things, certain prepetition claims of employees and taxing authorities. Accordingly, these liabilities may have been or may be satisfied in accordance with such First Day Orders. To the extent any payments were made on account of prepetition claims following the Petition Date pursuant to the authority granted to the Debtor under the First Day Orders, such payments have been included in the MOR (subject to the notes and statements and limitations provided herein).

Reservation of Rights

The Debtor reserves all rights to amend or supplement the MOR in all respects, as may be necessary or appropriate. Nothing contained in the MOR shall constitute a waiver of any of the Debtor’s rights or an admission with respect to any claim against the Debtor or otherwise in connection with this chapter 11 case

Specific MOR Disclosures

Part 1: Cash Receipts and Disbursements

Pursuant to the Initial Interim DIP Order, fees and expenses of estate professionals were placed into the Professional Fees Account (as defined in the Initial Interim DIP Order) maintained by the Debtor. The transfer of such funds to the Professional Fee Account were treated as a transfer between Debtor accounts, and, therefore, were not treated as a distribution in Part 1(c). Professional fees will be treated as a disbursement in the reporting period in which they are paid to the applicable professionals.

Similarly, pursuant to the interim order approving, among other things, the Debtor’s proposed form of adequate assurance of payment to utility companies [Docket No. 56] (the “Interim Utilities Order”), the Debtor deposited $75,000 into the Utility Deposit Account (as defined in the Interim Utilities Order) maintained by the Debtor. Such transfer was treated as a transfer between Debtor accounts, and, therefore, was not treated as a distribution in Part 1(c).

²  The Initial DIP Facility was replaced following the reporting period pursuant to the Interim Order (A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 176]. There were no draws under the replacement facility during the Reporting Period.

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 16 of 23

Notes to Part 2: Asset and Liability Status

Unless otherwise noted, all asset and liability information included in the MOR reflects net book value, which may differ from current market value. As set forth above, this information has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtor believes that the financial information presented in the MOR could be subject to change, including material change. Asset and liability information includes intercompany claims and other assets and liabilities which may not be settled in cash.

The Debtor continues to pay postpetition invoices on account of postpetition goods provided and services rendered in the ordinary course of business.

Given the Petition Date did not occur at month end, certain prepetition and postpetition liability balances are estimated. The Debtor has sought to assign liabilities to the prepetition and postpetition periods based on the information available as of and at the time the MOR was prepared. As additional information becomes available, the allocation of liabilities between prepetition and postpetition periods may change. The Debtor reserves the right to amend the balances as it deems appropriate and any such amendments will be reflected in future MORs

The amounts listed as “Prepetition Secured Debt,” “Prepetition Priority Debt” and “Prepetition Unsecured Debt” are preliminary and are subject to ongoing review and reconciliation by the Debtor. All amounts and classifications are subject to material adjustments.

Regarding Part 2c, the Debtor does not hold inventory; therefore, no inventory valuation method is applicable.

Notes to Part 7: Questionnaire

Regarding Part 7a, and as mentioned above, the Debtor is authorized to pay certain prepetition claims and obligations pursuant to the First Day Orders.

Regarding Part 7g, the Debtor drew $10,500,000 under the Initial DIP Facility during the Reporting Period. The Debtor utilized the funds drawn under the DIP Facility to fund, among other things, the Debtor’s business operations and its chapter 11 case.

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 17 of 23

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.		Case No: 26-10989
Schedule of Post-Petition Borrowing Activity		Reporting Period: June 23 – June 30, 2026

The Debtor hereby submits this attestation regarding postpetition borrowing during the period of June 23, 2026 through June 30, 2026.

In accordance with the Interim Order (A) Authorizing the Debtor to Obtain Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 63], the Debtor drew $10,500,000 under the Initial DIP Facility during the Reporting Period.³

/s/ Nikunj Jain				August 6, 2026
Signature of Authorized Individual				Date
Nikunj Jain				Interim Chief Financial Officer
Printed Name of Authorized Individual				Title of Authorized Individual

³  The Initial DIP Facility was replaced following the reporting period pursuant to the Interim Order (A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 176]. There were no draws under the replacement facility during the Reporting Period.

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 18 of 23

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.		Case No: 26-10989
Schedule of Payments on Prepetition Debt		Reporting Period: June 23 – June 30, 2026

All payments made by the Debtor during the Reporting Period (and included in the disbursements reported in this MOR) were authorized under various final orders granted by the Court, which authorized the Debtor’s various motions that were filed following the commencement of the chapter 11 case.

/s/ Nikunj Jain				August 6, 2026
Signature of Authorized Individual				Date
Nikunj Jain				Interim Chief Financial Officer
Printed Name of Authorized Individual				Title of Authorized Individual

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 19 of 23

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.		Case No: 26-10989
Schedule of Payments on Prepetition Debt		Reporting Period: June 23 – June 30, 2026

The Debtor hereby submits this attestation regarding payments to insiders during the period of June 23 through June 30, 2026.

With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements.

No non-cash transfers were made during this reporting period.

/s/ Nikunj Jain				August 6, 2026
Signature of Authorized Individual				Date
Nikunj Jain				Interim Chief Financial Officer
Printed Name of Authorized Individual				Title of Authorized Individual

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 20 of 23

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.		Case No: 26-10989
All bank statements and bank		Reporting Period: June 23 – June 30, 2026
reconciliations for the reporting period

The Debtor hereby submits this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and journal entries.

The Debtor’s standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting period. I attest that each of the Debtor’s bank accounts has been reconciled in accordance with their standard practices.

/s/ Nikunj Jain				August 6, 2026
Signature of Authorized Individual				Date
Nikunj Jain				Interim Chief Financial Officer
Printed Name of Authorized Individual				Title of Authorized Individual

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 21 of 23

Sangamo Therapeutics Inc.

MOR #1 - Statement of cash receipts and disbursements

Units (i.e. $ in 000s)

		06/23/2026 - 06/30/2026
Receipts
Operational Receipts		$	3
DIP Draw		$	10,500
Total Receipts		$	10,503
Operational Disbursements
Payroll & Benefits		$	241
Rent & Facilities		$	3
Other Operating Disbursements		$	2
Total Operational Disbursements		$	246
Restructuring Disbursements
DIP Interest & Fees			732
Total Restructuring Disbursements		$	732
Net Cash Flow		$	9,525
Cash, cash equivalents, and restricted cash, beginning of period		$	4,857
Cash, cash equivalents, and restricted cash, end of period		$	14,382

1 of 3

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 22 of 23

Sangamo Therapeutics Inc.

MOR #1 - Balance sheet

Units (i.e. $ in 000s)

		As of
		6/23/2026				6/30/2026
Assets
Cash, Cash Equivalents and Restricted Cash		$	4,857			$	14,382
Accounts Receivables			464				500
Other Current Assets			3,488				3,303
Total Current Assets		$	8,810			$	18,186
Property, Plant & Equipment (Net)		$	9,703			$	9,644
Right of Use Assets			2,761				2,747
Other Non-Current Assets			779				779
Investments in Subsidiaries			115,762				115,762
I/C Receivables - Non-Current			5,945				5,970
Total Non-Current Assets		$	134,949			$	134,902
Total Assets		$	143,759			$	153,087
Liabilities and Stockholders’ Equity
A/P and Accrued Liabilities		$	27,899			$	30,620
Compensation and Benefits Liabilities			13,038				13,304
DIP Loan Payables			—				10,500
Other Current Liabilities1			9,199				9,001
I/C Payables - Current			42,765				42,651
Other Non-Current Liabilities1			23,827				23,678
I/C Payables - Non-Current			689				692
Total Liabilities		$	117,416			$	130,446
Total Stockholders’ Equity		$	26,342			$	22,642
Total Liabilities and Stockholders’ Equity		$	143,759			$	153,087

Notes:

¹  Includes Deferred Revenues and Lease Liabilities

2 of 3

Case 26-10989-CTG  Doc 268  Filed 08/06/26  Page 23 of 23

Sangamo Therapeutics Inc.

MOR #1 - Statement of operations (profit or loss statement)

Units (i.e. $ in 000s)

		06/23/2026 - 06/30/2026
Total Revenue		$	109
COGS			—
Gross Profit		$	109
Personnel & Staffing Costs1		$	634
R&D Expenses2			835
Selling Expenses			—
General and Administrative Expenses			241
Facilities & OH Expenses1			221
I/C Expenses2			80
Other Expenses2			3
Restructuring Expenses3			2,010
Depreciation and/or amortization			59
Total Operating Expenses		$	4,084
Unrealized FX (Gain)/Loss		($	217	)
Non-Operating (Income)/Expense			(3	)
Total Non-Operating (Income)/Expense		($	220	)
Net Profit/(Loss) for the Period		($	3,755	)

Notes:

¹  Considered under “General and Administrative Expenses” for MOR

²  Considered under “Other Expenses” for MOR

³  Includes professional fees and DIP loan fees accruals

3 of 3

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 795.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB